ANI Pharma exec reports restricted stock and tax shares

ANI Pharmaceuticals executive Christopher Mutz reported two equity-related transactions in company stock.

Rhea-AI Filing Summary

ANI Pharmaceuticals executive Christopher Mutz reported two equity-related transactions in company stock. On February 26, 2026, he acquired 21,306 shares of common stock through a restricted stock award that will vest in four equal annual installments on each anniversary of February 26, 2026.

On February 28, 2026, 2,221 shares of common stock were disposed of to cover tax withholding in connection with the vesting of 4,342 previously granted restricted shares, a transaction exempt under Rule 16(b)-3. After these transactions, Mutz directly owned 103,925 shares of ANI Pharmaceuticals common stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Mutz Christopher

Role HEAD OF RARE DISEASE

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	2,221	$73.90	$164K
Grant/Award	Common Stock	21,306	$77.15	$1.64M

Holdings After Transaction: Common Stock — 103,925 shares (Direct)

Footnotes (2)

1. F1. Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026.
2. F2. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,342 shares of restricted stock, the grant of which was previously reported.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ANI Pharmaceuticals (ANIP) report for Christopher Mutz?

ANI Pharmaceuticals reported that executive Christopher Mutz received a restricted stock award of 21,306 common shares and had 2,221 shares withheld to satisfy tax obligations tied to vesting restricted stock, leaving him with direct ownership of 103,925 common shares after these transactions.

Was the ANI Pharmaceuticals (ANIP) Form 4 a stock sale by Christopher Mutz?

The Form 4 does not show an open-market sale. It reports a restricted stock award and a tax-withholding disposition of 2,221 shares in connection with vesting of 4,342 restricted shares, a transaction characterized as exempt under Rule 16(b)-3 rather than a discretionary stock sale.

How many ANI Pharmaceuticals (ANIP) shares did Christopher Mutz acquire in the award?

Christopher Mutz acquired 21,306 shares of ANI Pharmaceuticals common stock through a restricted stock award. According to the filing, these shares will vest in four equal annual installments on the first, second, third, and fourth anniversaries of February 26, 2026, subject to the award’s terms.

How many ANI Pharmaceuticals (ANIP) shares were used for tax withholding for Christopher Mutz?

The filing states that 2,221 ANI Pharmaceuticals common shares were withheld for tax purposes. This withholding related to the vesting of 4,342 previously granted restricted shares and is described as exempt under Rule 16(b)-3, indicating a tax-related disposition rather than an open-market sale.

What is Christopher Mutz’s ANI Pharmaceuticals (ANIP) share ownership after the reported Form 4?

After the reported award and tax-withholding disposition, Christopher Mutz directly owns 103,925 shares of ANI Pharmaceuticals common stock. This total reflects his holdings following the grant of 21,306 restricted shares and the withholding of 2,221 shares for tax obligations associated with restricted stock vesting.

How does the ANI Pharmaceuticals (ANIP) filing describe the vesting schedule of the new restricted stock award?

The restricted stock award granted to Christopher Mutz will vest in four equal annual installments. Vesting occurs on the first, second, third, and fourth anniversaries of February 26, 2026, meaning the shares become fully vested over four years, subject to the award’s conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 05:59 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mutz Christopher

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	HEAD OF RARE DISEASE

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		A(1)		21,306	A	$77.15	106,146	D
Common Stock	02/28/2026		F(2)		2,221	D	$73.9	103,925	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026.

2. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,342 shares of restricted stock, the grant of which was previously reported.

Remarks:

	/s/ Christopher Mutz, by attorney-in-fact Meredith W. Cook	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.